Zoetis Inc. $ZTS Holdings Boosted by Intellectus Partners LLC

Intellectus Partners LLC raised its position in shares of Zoetis Inc. (NYSE:ZTS) by 138.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 21,264 shares of the company’s stock after purchasing an additional 12,333 shares during the quarter. Intellectus Partners LLC’s holdings in Zoetis were worth $2,675,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of the business. Global Wealth Strategies & Associates purchased a new stake in Zoetis in the 4th quarter worth about $25,000. Lodestone Wealth Management LLC purchased a new stake in Zoetis in the 4th quarter worth approximately $30,000. KERR FINANCIAL PLANNING Corp acquired a new stake in shares of Zoetis during the 3rd quarter valued at $31,000. Holos Integrated Wealth LLC acquired a new stake in shares of Zoetis during the 4th quarter valued at $32,000. Finally, Elyxium Wealth LLC acquired a new position in shares of Zoetis in the fourth quarter worth $32,000. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Stock Up 1.5%

Shares of ZTS opened at $77.51 on Thursday. The company has a 50-day simple moving average of $101.99 and a 200-day simple moving average of $116.09. The firm has a market capitalization of $32.49 billion, a P/E ratio of 12.85, a P/E/G ratio of 1.25 and a beta of 0.75. The company has a debt-to-equity ratio of 2.80, a quick ratio of 1.91 and a current ratio of 3.15. Zoetis Inc. has a 52 week low of $72.38 and a 52 week high of $171.52.

Zoetis (NYSE:ZTS) last released its earnings results on Thursday, May 7th. The company reported $1.53 earnings per share for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). Zoetis had a return on equity of 66.85% and a net margin of 27.80%.The firm had revenue of $2.26 billion for the quarter, compared to analyst estimates of $2.30 billion. During the same period last year, the business earned $1.48 earnings per share. The firm’s quarterly revenue was up 2.9% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. On average, equities research analysts expect that Zoetis Inc. will post 6.89 earnings per share for the current year.

Zoetis Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Monday, July 20th will be issued a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a dividend yield of 2.7%. The ex-dividend date of this dividend is Monday, July 20th. Zoetis’s dividend payout ratio (DPR) is presently 35.16%.

Key Zoetis News

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: Some market commentary says Zoetis could still be a value opportunity, with one analysis describing the stock as a potential deep-value play with significant upside if the business stabilizes.
• Neutral Sentiment: Zoetis presented at the William Blair Growth Stock Conference, but no major new operating update from that event was highlighted in the headlines provided.
• Negative Sentiment: Multiple law firms announced or reminded investors about a class-action lawsuit alleging securities-law violations during the Jan. 14, 2025 to May 6, 2026 period, with several notices urging shareholders to seek lead-plaintiff status by July 27, 2026. These repeated legal alerts can weigh on the stock. Article Title
• Negative Sentiment: One article said Zoetis has underperformed its industry peers over the past year, reinforcing concerns about recent relative stock performance.
• Negative Sentiment: Investor notices from Robbins Geller, Levi & Korsinsky, the Schall Law Firm, Howard G. Smith, Bernstein Liebhard, The Gross Law Firm, DJS Law Group, and others all highlighted the ongoing lawsuit, increasing headline risk for ZTS.

Insider Activity

In other news, Director Frank A. Damelio bought 6,650 shares of the business’s stock in a transaction that occurred on Wednesday, May 13th. The stock was acquired at an average cost of $75.39 per share, for a total transaction of $501,343.50. Following the completion of the purchase, the director owned 21,458 shares of the company’s stock, valued at $1,617,718.62. This trade represents a 44.91% increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Paul Bisaro bought 2,000 shares of the business’s stock in a transaction that occurred on Wednesday, May 13th. The stock was purchased at an average price of $75.88 per share, with a total value of $151,760.00. Following the completion of the purchase, the director directly owned 27,862 shares of the company’s stock, valued at $2,114,168.56. This represents a 7.73% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last ninety days, insiders have bought 11,650 shares of company stock worth $886,384. Company insiders own 0.22% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the company. JPMorgan Chase & Co. lowered their target price on Zoetis from $190.00 to $130.00 and set an “overweight” rating on the stock in a research note on Friday, May 8th. Weiss Ratings downgraded Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday, March 27th. Stifel Nicolaus lowered their price target on Zoetis from $105.00 to $95.00 and set a “hold” rating for the company in a research note on Friday, May 22nd. UBS Group dropped their price objective on Zoetis from $130.00 to $99.00 and set a “neutral” rating on the stock in a report on Friday, May 8th. Finally, William Blair reaffirmed an “outperform” rating on shares of Zoetis in a research report on Monday, March 2nd. Six investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Zoetis currently has an average rating of “Hold” and an average price target of $133.92.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.